Index

a
absolute bioavailability 28
absorption, distribution, metabolism and excretion of a compound (ADME) 8, 9, 19, 43, 59, 135, 144, 261, 271
accelerated pathways 188–190, 196
active pharmaceutical ingredient (API) patent 297
preclinical development and clinical phase 1 107–108
preclinical development and clinical phase 2 111
active receptors 16
Active Substance Master File (ASMF) 347
adaptive trials design 171–172
adverse effects 10, 69, 81, 82, 84–85, 87, 89, 91, 93, 125, 211, 375
advisory boards 174
Advisory Committee (AC) meeting 197
agile development process 373–374
agonism 15–18
agonists 11, 16–17, 168
alliance management 323, 331–332
analysis populations 163, 166
analytical biomarker validation 66
analytical development
preclinical development and clinical phase 1 109–110
preclinical development and clinical phase 2 111
animal experimentation 37
3 R principles of 91
animal species selection 89
antagonism 15–18
antagonist 16–17, 24
anti-cancer drugs 87, 93–94
antigen content 385–386
antigenic drift 381
area under the concentration curve (AUC) 28–29
artificial intelligence 64, 78, 135, 261, 376
Arzneimittelmarkt Neuordnungsgesetz (AMNOG) 247
drug prices in Germany 251–252
study design 254
success in German market 253
assay costs for 48
of pharmacological 47–48
robustness of 48
assessment report (AR) 184, 198
assessment table 156
asset shaping stage, MA&P 238–239
ATP binding cassette 25, 49, 52
autophosphorylation 13

b
back-loaded 320
back or forward and backward translation 129–132
bankruptcy 341
basic patents 262, 296, 311, 313
basket trials 173

Principles of Biomedical Sciences and Industry: Translating Ideas into Treatments, First Edition.
Edited by Markus Hinder, Alexander Schuhmacher, Jörg Goldhahn, and Dominik Hartl.
© 2022 WILEY-VCH GmbH. Published 2022 by WILEY-VCH GmbH.
bedside to bench or backward translation 130–132
bench to bedside 121, 127, 129–131, 134
benchmark products 211, 219
benefit assessment 84, 146, 179, 233, 247–256
biased (hypothesis-driven) approach 68
biliary elimination 27
bioavailability (BA or F) 21, 28, 30–31, 82, 102
biochemical assays 47
biochips 366
biologics 81, 100, 104, 116, 167, 186, 187, 196–198
Biologics License Application (BLA) 116, 180, 196–197
biomarker(s) 64
development 65
drug development 73–75
modalities 69–73
use cases 75–77
validation 66
biomarker qualification program (BQP) 74–75
biopharmaceutical classification system (BCS) 102–103
biopharmaceutical drug development 2–4
biopharmaceutical industry
FTO issues in 300–301
intellectual property protection in 294–295
regulatory environment 177–181
biopharmaceutical innovation 1–5
biotech funding
exit options 342–343
seed funding 335–336
series A 336–339
series B 339–341
series C 341–342
venture debt 341
biotechnology patents 307–308
black-box 5, 255
blood-brain barrier (BBB) 21–22
blood transfusion 365
board of directors 338, 342
brand differentiation 236
budget impact 230–231, 243
Business Development & Licensing (BD&L) 318
alliance management 331–332
Case-in-point 1 326–327
Case-in-point 2 327
Case-in-point 3 328–329
Case-in-point 4 330
Case-in-point 5 331
collaborations, types 318–319
commercial or distribution partnerships 320–321
due diligence 327–328
evaluation process 324–326
letter of intent 329–330
licensing agreements 319–320
negotiation and contract closure 330–331
other types of agreements 321–322
research collaborations 321
structured approach 322–324
tech transfer agreements 322
term sheet 329, 330
business model 257, 305, 317, 318, 332, 336
of Prionics 312
business plan 139–140, 142, 333, 336–337

C
$C_{\text{max}}$ 28, 29, 169
$C_{\text{trough}}$ 28, 29
candidate list 346
candidate selection 39, 56, 58–60, 92, 140, 144
CANTOS study 132
carcinogenic potential 87, 95
Case-in-point A 192
Case-in-point B 193
Case-in-point 1, BD&L 326–327
Case-in-point 2, BD&L 327
Case-in-point 3, BD&L 328–329
Case-in-point 4, BD&L 330
Case-in-point 5, BD&L 331
CD28 agonist 168
cell death 14, 146
cellular assays 47, 55
cellular biomarkers 71
cellular pathology 8
cellular test systems 42
chemical antagonists 17
Chemical Genomics 42–43
chemical libraries 52

compounds in 53–54
DNA-encoded chemical libraries 54–55
chemical target validation 42–43
chemistry, manufacturing and controls (CMC) 181, 182
biopharmaceutical classification system 102–103
morphology and polymorphism 105–106, 107
NDA submission 116
physico-chemical characteristics 101–102
stability investigations 104, 105
steps to product launch 116
transition from research to development 100–101
chemoluminescence measurement 48
classical forward translation 129–130, 134
clearance (CL), of compound 27–28
clinical biomarker validation 67
clinical chemistry 361, 363–365, 372
clinical development plan (CDP) 81, 146, 166
clinical development, stages of 154
clinical drug development definition and framework 152
stages of 152–155
clinical evaluation 146, 180, 208, 211, 214, 217, 219
clinical studies
graphical study design 156–160
schedule of activities 156–160
written subject information 156
clinical study protocol (CSP) 155–156
clinical trail(s)
assessing treatment effects in 164
basic framework and elements for 155
design elements of 162
logistic aspects of 163
operational activities and roles in 165
purposes of 160
clinical trial application (CTA) 110, 111, 166, 180, 184–185, 260–261
clinical workflow 366–367
coagulation tests 364–365
COGs-plus model 320
commercial or distribution partnerships 320–321
commercial risks 272
common technical document (CTD) 112, 116, 179, 182–185, 194
comparative products 211
comparative/incremental health benefit 230
Competent Authority (CA) 110, 372
competitive antagonists 17
complaint handling and corrective and preventive action (CAPA) 371
composite biomarker 67
conditional reimbursement 241
Confidentiality Agreement (CDA) 324, 327
confirmatory phase 1 126, 143, 148, 194, 261
continuous patent portfolio management 313
contract closure 317, 322, 327–328, 330–331
cost benefit analysis (CBA) 225, 233, 286
cost planning 271–272
cost utility analysis (CUA) 225, 233
cost-effectiveness analysis (CEA) 225, 233
cost-minimisation analysis (CMA) 234
country strategy 313
coverage with evidence development (CED) 241
COVID-19 pandemic 166–167
critical material attributes (CMA) 113
critical process parameters (CPP) 113
critical quality attributes (CQA) 113
cross-sectional biomarker 68
customer requirements 211–212, 216, 219
cytochrome P450 (CYP) enzymes 20, 23–25, 27
del data mining 102, 131, 132, 134
data monitoring committee (DMC) 172, 174
data safety and monitoring boards (DSMB) 174
74-Day letter 197
120-Day safety report 197
de novo classification 371
de-novo drug design approach 51
death domains 14
death receptors 14
decentralised procedure (DP) 198
decision making process 140, 231
descriptive biomarker 68
design and development journal 216
design and development log 216
design and development plan (DDP) 140–141, 144, 212–213
design and development validation 219–222
design and development verification 218
design change 216, 217
design freeze 217
design input 216–219
design output 216–218
design requirements 216
design specifications 216
design validation 217
design verification 217, 219
diagnostic biomarker 65, 67, 69, 74
digital biomarkers 63, 65, 67, 73, 78
digitalization 166–167
digitization and artificial intelligence 376
direct effect 11
disease-related biomarker 68
DNA-encoded chemical libraries (DEL libraries) 54–55
dose limiting toxicities (DLTs) 146, 168
dose-range finding studies (DRF) 31, 33, 92, 180
dose-ranging studies 170–171
dose-response relationship 18
dosing regimen 27, 82, 120, 135
Dossier preparation 194, 254
drug development implications 18
for orphan/rare diseases 187–188
drug development pathway/process (DDP) 31, 33, 69, 74, 82, 89, 119–135, 139–144, 150, 212–213, 219–221, 240
drug discovery 38–40, 259, 261
and development practice 128
pharmacogenetic links to phenotype 41
phenotypic screening 41
target and its pathway(s) 41
drug formulations 104
drug marketing authorisation 238
Drug Master File (DMF) 347–348
drug prices 242
in Germany 251–252
drug product
life cycle management 298
loss of exclusivity (LoE) 299–300
preclinical development and clinical phase 1 108–109
preclinical development and clinical phase 2 111
regulatory data protection 299
drug projects 258–260, 273–274, 276, 278
market 122
Index

Drug purchasing 228–229
Drug-related biomarker 68
Drug repurposing 128
Drug safety 56, 331
Preclinical evaluation 39
Dual Blade Cutter 351
due diligence 317, 323–325, 327, 328, 340
dynamic biomarker 68

E
Early drug development phase 126
Early patient access 240
Efficacy profile 19, 141
Efficacy studies 130, 171
Embryo-fetal development 94–95
End-of-phase (EoP) 2 meetings 181
Endpoint adjudication committees (EAC) 174
Enzyme-linked immunosorbent assay (ELISA) 71, 77
Enzymes 14
  Activation 14, 15
  Associated receptors 12–14
  Inhibition 15
Equivalent devices 211
EUnetHTA 185, 243
European Drug Master File (EDMF) 347
European In Vitro Diagnostic Regulation (IVDR) 372
Evaluation process, BD&L 324–326
Evidence building stage, MA&P 239
Exit options 342–343
Expiry date, of patent 289, 294
Exploratory phase 1, 126
Expressed sequence tags (ESTs) 307
External reference pricing (ERP) 234–235
Extracellular signal-regulated kinases (ERK) 13

F
Fast switching valves 352, 55
Fee-for-service 321, 338
Financial projections 336–337
First in human (FIH) trials 86
Clinical development 167–169
Data package required for 87
Large (bio)molecules and oncology compounds 87–89
Safe starting dose in 93
Study 76, 169
First-in-patients clinical trials (Phase 1) 181
First pass effect (FPE) 19–20, 21, 23, 27
Fluorescence measurements 48
Fluorescence or silver in-situ hybridization (FISH/SISH) 366
Fluorescence resonance energy transfer (FRET) 48
Forward translation approach 126
Forward vs. reverse/back-translation 126–129
Fragment-based drug discovery 49
Freedom-to-operate (FTO) principle 284, 292–294, 300–302, 310, 313
Front-end loading 273, 274
Front-loaded 319
Full agonists 16–17
Functional antagonists 17

G
Genetic target validation 42
Genotoxicity 82, 88, 90, 92, 349–350
Genotype-phenotype relationships 123
Germany, Federal Joint Committee (G-BA) 225, 228, 248, 250, 252, 254–255
Glomerular filtration 22, 25–26
Glomerular filtration rate (GFR) 26
Go confirmatory development 148–149
Go First in Human (FIH) decision 144–147
Go IND decision 145
Go IND enabling 142–144
Go Phase 2 decision 148
Go/No Go First in Human (FIH) 144–146
Go/No go Phase 2 146–148
G-protein-coupled receptors (GPCRs) 11–12, 49, 51
graphical study design 156–160
guanylyl cyclase activity 12–13

h
haematology tests 364, 365
health authorities (HA)
  early consultations with 185
  pre-submission meetings 194–195
review of registration dossiers 196–199
health economics 231–234, 238
health outcomes 230–232, 241, 243
health technology assessment (HTA) 232
  committees 228
  process 233, 234
  reach 242–243
healthcare challenges 226–227
hemagglutination inhibition (HI) 384
hemagglutinin (HA) 380, 383–385, 387
high content screening 48
high throughput screening (HTS) 43, 45–52, 54, 261
histopathology 91, 366
homology modelling 50

i
imaging biomarkers 70, 72–73
immunoblotting 77
immunologic memory 379
immunological tests 364
implementation and adjusting stage, MA&P 239–240
in vitro diagnostics (IVD) 345, 357–358, 361, 367, 370–372, 374, 376
tests 360
in-vitro dissolution technique 103
incremental budget impact 231, 243
indirect effects 11
individualized dosing 34
influenza vaccines 385
  acceptability 387–393
  antigen content 385–386
  challenge 383–384
  formulation 386
  history 378–383
  intradermal administration 386–387
  mechanisms of 384
influenza virion 380
initial public offering (IPO) 339, 342
innovation, pharmaceutical 257
innovative valve technology 352
Institute for Clinical and Economic Review (ICER) 235, 242
integrated development plan (IDP) 166
integration technology 353–355
integrative & iterative learning cycles 128, 134
intellectual property department 301
intellectual property protection 294–301
intellectual property rights 186, 282–284, 294, 300
intended purpose 204, 208, 216
intended use 94, 109, 207–209, 213, 216, 219, 294, 371
intent-to-treat population (ITT) 163
international/external reference pricing (ERP) 235
intestinal elimination 27
intradermal administration (ID) 386–387, 389–393
invasive biomarker 68
inverse agonists 16
Investigational Medicinal Product Dossier (IMPD) 110, 149, 184–185
investigator’s brochure (IB) 166, 180–182, 185
ion channels 9, 11–12, 44, 47, 380
ionotropic receptors 12
ISO 10993 346, 349–350
ISO 13485:2016 204–205, 212, 216–219

j
c-Jun N-terminal kinases (JNK) 13
juvenile toxicity 95
**k**

knockout-phenotypes 42

**l**

laboratory developed tests (LDTs) 367–369

laboratory diagnostics
  automation 375
  clinical chemistry 363–364
  clinical workflow 366–367
  definition 358–361
digitization and artificial intelligence 376

haematology and coagulation tests 364–365

histopathology 366

history 362

immunological tests 364

industry 361–362

microbiology 365

molecular diagnostics 365–366

molecular testing 375

personalized/precision medicine 375

point of care testing 375

quality management 367–370

R&D process 373–374

regulatory approval 370–373

test types 358–359

workflow 362–363

laboratory workflow 362–363

LADME scheme (liberation, absorption, distribution, metabolism and excretion) 19

late-stage development phase 100, 120, 124–126, 320

lead identification process 44–45

lead optimization 37, 38, 41, 51, 54–59, 101, 127, 261, 270–272

legal manufacturer 206, 207, 214, 372

Letter of Intent (LoI) 329–330, 337

licensing agreements 318–322, 330

Licogliiflozin 129, 130

ligand-based virtual screening 50

ligand-binding site 44

ligand-controlled ion channels 11, 12

ligand-(L)-receptor-(R)-interaction 11

loading dose (LD) 22, 29–31

longitudinal biomarker 68

loss of exclusivity (LoE) 299–300, 302

**m**

MABEL approach 93, 94

Madrid Protocol 281, 282

managed entry agreements (MEAs) 235, 239–242

Mantoux technique 386

manufacturing units 100

market access 227
decision tool for 231–234
gatekeepers 228
trends 242–243

market and competition 336

market entries 237–240

market risks 272

marketing authorisation application (MAA) 181, 185, 190, 191

marketing authorization 4, 85, 87, 100, 112–116, 122, 127, 185, 186, 190, 198, 226, 235, 238, 296–299, 321, 340

masking proteins 44

Material Transfer Agreement (MTA) 329

matrix protein 2 ectodomains (M2e) 384

maximal safe starting dose 93

maximum tolerated dose (MTD) 144, 168

mechanistic biomarker 68

mechanistic studies pharmacodynamic (PD) effects 7, 31, 68, 69, 74–77, 127, 129, 130, 145, 152, 169

medical device regulation (MDR) 203–205, 207, 208, 210, 211

essential safety and performance requirements 211

medical devices (MD)
design and development 205
design and development validation 219–222
design and development verification 218
**medical devices (MD) (contd.)**
- developing 210, 212
- planning and executing 216–217
- post-market phase of 214–215
- product commercialization 206–208
- product realization 205
- qualified input from interested parties 212–215

**medical grade plastics (MPG) 345–350**

**Michaelis constant (Km) 15**

**microbiology 365**

**micro-injection system 377, 390, 391**

**mid-cycle communication 197**

**minimum anticipated biological effect level (MABEL) approach 93, 94**

**mission statement 265, 267, 268**

**mixed-function monoxygenase 23**

**molecular biomarkers 71–72**

**molecular diagnostics 365–366**

**monoclonal antibodies (mAbs)**
- target specificity of 122

**multiple ascending dose (MAD) 153, 158, 168**

**mutual recognition procedure (MRP) 198**

### n

**NADPH (nicotinamide adenine dinucleotide phosphate) 23**

**NBTS 329–331**

**negotiation and contract closure 330–331**

**net present value (NPV) 143, 259, 275–278, 324, 327, 370**

**neuraminidase (NA) 380, 385, 386**

**neurotransmitters, transporters for 14**


**next generation sequencing (NGS) 75, 365, 366, 375**

**Non-Disclosure Agreement (NDA) 99, 184, 188, 189, 196, 324**

**non-competitive antagonists 17**

**non-GLP dose-range-finding studies (DRF) 31, 33, 92, 180**

**non-invasive biomarker 68**

**non-patentable subject matter 285**

**non-receptor-mediated effects 14–15**

**no-observed-effect-level (NOAEL) 28, 81, 85, 89–91, 93, 168**

**Notified Body (NB) 211, 346, 372**

**Nuclear Export Protein 380**

**numbers-needed-to-treat (NNT) 74**

### o

**oncology trials 173**

**oral formulations 28, 102**

**oral glucose tolerance test (OGTT) 130**

**The Orange Book 300, 302**

**Otamixaban 129–130**

**outcomes-based agreement (OBA) 241**

**outsourcing 163, 311, 313**

### p

**paediatric diseases 186–187**

**Paediatric Investigation Plan (PIP) 186, 192, 193, 195**

**paediatric study plan (PSP) 186, 192**

**parallel indication expansion 128**

**partial agonists 16**

**patent(s)**
- active pharmaceutical ingredient(s) 297
- in biomedical sciences and industry 306–309
- enforcement of 313
- ethics 308–309
- expiry date of 289
- how to obtain 286, 287
- industrial design right 309–310
- ownership of 286
- sale of 291

**Patent Cooperation Treaty (PCT) 288, 289**

**patent exclusivity 262, 299**

for pharmaceutical drug product 296–298
patent rights 282, 284–292, 294, 314
value and use of 291–292
patent term extensions (PTE) 298–299
patentability criteria 285–286
patenting
  an invention 291
  procedure 287–291
pathway biomarkers 75
patient reported outcomes (PROs) 167
patient risk sharing agreement 241
PAT-INFORMED 300, 302
payers
  requirement 236
  and value assessment 229–231
PCSK9 41, 44, 131–132
  identification 131–132
peak-to-trough-ratio 28
peri-natal development 95
periodic safety update reports (PSURs) 199
pharmaceutical phase 8, 9
pharmaceutical R&D projects 260, 273
pharmaceutical target 40
pharmacodynamic (PD) effects
  mechanistic studies 169
pharmacokinetic-pharmacodynamic (PKPD) modeling 31, 33, 145
pharmacokinetics (PK) 8, 19
  absorption 21
  administration and liberation 19, 21
  biliary elimination 27
  characteristics of 33
  distribution 21–22
  excretion 25–27
  information 146
  intestinal elimination 27
  metabolism/biotransformation 22–23
  phase I reaction 23–25
  pulmonary elimination 27
  quantitative 27–30
  renal elimination 25–26
pharmacological effect 9, 11, 22, 56, 59, 68, 93
pharmacology
  drug development, implications for 31–34
  pharmaceutical phase 8
  pharmacodynamics 9
  pharmacokinetics 8
pharmacovigilance 199, 273, 327, 330, 331, 387
pharmacovigilance agreement 330, 331
phase I reaction
  oxidation 23–24
  reduction and hydrolysis 24
phase II reactions 24, 25
phase III reactions 25
phenotypic assays 46, 47
phenotypic screening 41, 51–52, 54, 180
physiologically based PK (PBPK) models 30, 31
PK/PD relationships 68, 76
pKa value 26, 101, 102
p38 kinases 13
plasma concentration 22, 26, 27
plasma protein binding (PPB) 21, 26
platform technologies 71, 335
platform trials 173
point of care testing (PoCT) 375
polymerase chain reaction (PCR) 54, 55, 365, 366
polymorphism 24, 25, 41, 68, 104, 105–107
poor metabolizer (PM) 24
population PK (PopPK) models 30, 31, 33
portal vein system 20
portfolio management 257–278, 305, 311, 313, 319
portfolio of therapeutic molecules 335
posology 125, 142, 143
post launch 255, 373
post marketing surveillance 371
post negotiation 255
post-marketing/real-world evidence (RWE) 128, 241
postnatal development 95
PPV 369, 370
pre-approval inspection (PAI) 116, 197
pre-launch strategy 254
pre-NDA 195
pre-submission meetings 188, 194–195
precision medicine 34, 63, 64, 78, 135, 375
preclinical development 100, 107–112, 261, 263
preclinical development and clinical phase 1
active pharmaceutical ingredient 107–108
analytical development 109–110
drug product 108–109
FIH study 110
preclinical development and clinical phase 2
active pharmaceutical ingredient (API) 111
analytical development 111
drug product 111
preclinical development and clinical phase 3 111–112
preclinical safety 60, 82, 83
predefined stopping rules 172
predictive biomarker 65, 69, 75, 76
premarket approval (PMA) 209, 371, 372
premarket notification 371
price negotiation 243, 247–256
price setting 234–237
price transparency 242
pricing policy 234
pricing structure 249–251
principal investigator (PI) 156, 174
Prionics 305–314
business model of 312
probability of technical and regulatory success (PTRS) 273, 275, 276
prodrugs 20, 21
product commercialization 206–208
product differentiation 236
product label 175, 193
product life cycle 206, 218, 247, 318
product realization 205, 212, 217–219
prognostic biomarker 65, 68, 69
project leader 265–267, 270
project lifecycle 269, 270, 272
project management 258, 263–269, 271, 272, 274, 275, 332, 373
project phases 260, 263, 269–272
project sponsor 265, 266, 270
project team members 266, 267
promoting greater transparency 242
proof of concept (PoC or cPoC) 1, 73, 76, 101, 110, 120, 121, 123, 125, 126, 133, 135, 141, 143, 153, 169–170, 172, 181, 190, 260, 261, 263, 272, 274, 339
proof-of-clinical concept (PoC) 1, 101, 120, 135, 141, 153, 169, 170, 181, 190, 260, 261, 272, 274
proof-of-mechanism (PoM) 76, 125, 153
protein-protein interactions (PPI) 40, 44
pseudo-polymorphs 105
pulmonary elimination 27
q
quality agreement 330, 331, 348
quality management 367, 370
commercial test 367
laboratory developed tests 367–369
test performance characteristics 369–370
quality management system (QMS) 204, 205, 212, 213, 371
quality target product profile (QTPP) 113
QUALY 232
quantitative decision making (QDM) 170
quantitative pharmacokinetics
accumulation and loading dose 29–30
area under the concentration curve 28
bioavailability 28
$C_{\text{max}}$ 28
$C_{\text{trough}}$ 28
clearance (CL), of compound 27–28
dosing regimen 27
half-life 29
induction and maintenance dose 30
peak-to-trough-ratio 28
volume of distribution 29

radioactive measurements 48
raising capital 292, 337
R&D process, phases
development 261
real-world evidence (RWE) 128, 241
receiver-operating characteristics (ROC) curve 67, 69, 370
receptor antagonists 17
receptor-mediated effect 14–16
receptors
agonism and antagonism 15–18
with associated tyrosine kinases 13
with guanylyl cyclase activity 13
and ion channels 11–15
serine/threonine kinases 13–14
recommended phase 2 dose (RP2D) 146
regenerative medical products (RMPs) 190
regenerative medicine advanced therapy (RMAT) 188–190
regulatory data exclusivity 299
regulatory data protection (RDP) 299, 300
regulatory stability studies 112–114
regulatory uncertainties 272
reimbursement price level 250
reimbursement process 1, 225, 230, 236–237, 240, 249–251
relative bioavailability 28
renal elimination 25–27
reporting member state (RMS) 184
reproducibility crisis 123
reproduction effect 82
reprotoxicology 94
research collaborations 318, 319, 321, 330
response biomarker 68, 69
restriction of certain hazardous substances (RoHS) 346
consistency of formulation 347–348
ISO 10993, 349–350
security of supply 348
return of investment (ROI) 143, 276, 278, 339
risk adjusted net present value (rNPV) 143, 276, 277
risk-adjusted or expected NPV (rNPV or eNPV) method 276
risk assessment 3, 18, 60, 83–85, 87, 89, 90, 92, 94, 96, 142, 143, 182
risk benefit assessment 146, 179
risk management 166, 195, 204, 208, 209, 214, 258, 269, 272–274
RNA viruses 380
role, project leader 267

safety and performance requirements 211, 216, 218
safety biomarker 69
safety margins 28, 33, 34, 90, 91, 127, 145
safety pharmacology 82, 87, 88, 92
safety population (SP) 163
safety window 84
safety/tolerability profile 141
Sakigake 190
sample size calculation 156, 160–161
sampling rules 172
seed financing 335
sensors 73, 78, 166–167
serendipity 128, 129, 132–134
series A financing
  alternatives to venture financing 338–339
team building 338
valuation 338
signal transduction 12–14, 44
Sildenafil 133–134, 236
single ascending doses (SAD) 168
Smad proteins 14
small interfering RNA (siRNA) 42, 43, 306
Special Protocol Assessment (SPA) 192
Spider Diagrams 58
stage gate process 278, 373, 374
standard of care (SOC) 112, 141, 160, 170, 238, 324
  product 324
static biomarker 68
steering committees (SC) 174, 268
stepwise approach 328
structure-activity relationships (SAR) 45, 49, 51, 53, 92
structure-based drug design (SBDD) 49
  focused screen 49
  fragment-based drug discovery 49
structured approach 264, 322–324
study design 91, 95, 156–162, 171, 172, 190, 192, 254
substances of very high concern (SVHC) 346
substrate excess 15
substrate saturation 15
supplementary protection certificates (SPC) 186, 299
surrogate biomarker 65, 69, 75
susceptibility/risk biomarker 69
target cost of goods (COGs) 142, 146, 320, 328
target identification 37, 40, 127, 261, 270
  sources for 41
target marketing profile (TMP) 142
target organs 82, 90, 92
target out-licensing profile (TOP) 142, 143
target product profile (TPP) 56, 58, 108, 113, 125, 141–142, 146, 150, 153, 166, 170, 268, 277, 324, 326, 327
target protein
  preventing formation of 43
target validation 42
  chemical 42, 43
  genetic 42
team building 338
tech transfer agreements 318, 322
technical risks 272
temporary project 263
Term Sheet (TS) 327, 329–330, 333, 334, 337, 340
therapeutic drug monitoring 34, 363
therapeutic index (TI) 18, 29, 38, 81, 84–85, 270
therapeutic range, of substance 18, 22, 143
therapeutic reference pricing (TRP) 234–235
time planning 271
time-resolved fluorescence (TRF) 48
top down approach 326
toxicological
  late-stage drug development 94–96
  for safety evaluations 85–89
toxicological framework 83–84
toxicological project
  stage of development 92–93
toxicology 1, 5, 81–97, 126, 144, 168, 180, 182, 184, 328
trade secret 282, 283, 286, 310, 319, 347
translational medicine (TM)
  back or forward and backward translation 129–132
backward translation 130–132
bedside to bench 130–132
bench to bedside 129–132
classical forward translation 129–130
definitions and history 120–121
failed translation 122–123
forward vs. reverse/back-translation 126–129
learning and confirming paradigm 124–126
models predictivity 123–124
serendipity 132–134
translatability gap 123–124
transporters 7, 10, 11, 14, 25–27, 44, 47
tubular reabsorption 25, 26
tubular secretion 25, 26
tumor necrosis factor (TNF) receptors 12, 14, 128
turnover model 31
Tyrosine kinase receptors 12, 13
Tyrosine kinases 12, 13

U
Umbrella Organisation of the Statutory Health Insurers (GKV-SV) 248, 250, 251
umbrella trials 173
unbiased (hypothesis-free) approach 68
unique selling point (USP) 103, 110, 141
unique selling proposition 141
usability engineering team 208
user needs 211, 216

V
vaccinia 378
validated language 166
validation of platform 335
value-added benefits 243
value assessment 229–231
value-based approach 243
value-based pricing (VBP) 225, 231, 235–236, 242
demand for 242
venture debt 341
venture financing 338–339
venture philanthropy 339
virtual screening 50
ligand-based 50
structure-based 50–51
virus neutralization (VN) 384
vitrectomy 350–352
voice of customer (VOC) 211
voltage-controlled channels 12
volume of distribution (V) 22, 29, 30
Voluntary Harmonisation Process (VHP) 184

W
work breakdown structure (WBS) 267, 268, 271
World Intellectual Property Organization (WIPO) 283, 288, 302, 303
written subject information 156, 172